MX357678B - Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43). - Google Patents

Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43).

Info

Publication number
MX357678B
MX357678B MX2014005048A MX2014005048A MX357678B MX 357678 B MX357678 B MX 357678B MX 2014005048 A MX2014005048 A MX 2014005048A MX 2014005048 A MX2014005048 A MX 2014005048A MX 357678 B MX357678 B MX 357678B
Authority
MX
Mexico
Prior art keywords
tdp
specific binding
binding molecules
variants
derivatives
Prior art date
Application number
MX2014005048A
Other languages
English (en)
Spanish (es)
Other versions
MX2014005048A (es
Inventor
H Weinreb Paul
Nitsch Roger
Hock Christoph
Grazia Barenco Montrasio Maria
Montrasio Fabio
Grimm Jan
Baeriswyl Jean-Luc
Coomaraswamy Janaky
Quintero-Monzon Omar
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of MX2014005048A publication Critical patent/MX2014005048A/es
Publication of MX357678B publication Critical patent/MX357678B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
MX2014005048A 2011-10-28 2012-10-26 Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43). MX357678B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553113P 2011-10-28 2011-10-28
PCT/IB2012/002905 WO2013061163A2 (en) 2011-10-28 2012-10-26 Tdp-43 specific binding molecules

Publications (2)

Publication Number Publication Date
MX2014005048A MX2014005048A (es) 2014-11-10
MX357678B true MX357678B (es) 2018-07-19

Family

ID=47720540

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014005048A MX357678B (es) 2011-10-28 2012-10-26 Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43).
MX2018008680A MX2018008680A (es) 2011-10-28 2014-04-25 Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018008680A MX2018008680A (es) 2011-10-28 2014-04-25 Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).

Country Status (18)

Country Link
US (3) US9587014B2 (OSRAM)
EP (2) EP3964524A1 (OSRAM)
JP (3) JP6240611B2 (OSRAM)
KR (2) KR102032080B1 (OSRAM)
CN (1) CN104159918B (OSRAM)
AU (1) AU2012327211C9 (OSRAM)
BR (1) BR112014010161B1 (OSRAM)
CA (2) CA3112082A1 (OSRAM)
CL (1) CL2014001074A1 (OSRAM)
EA (1) EA032003B1 (OSRAM)
ES (1) ES2883212T3 (OSRAM)
IL (2) IL232219B (OSRAM)
MX (2) MX357678B (OSRAM)
MY (1) MY167795A (OSRAM)
PH (1) PH12014500940A1 (OSRAM)
SG (1) SG11201401735WA (OSRAM)
WO (1) WO2013061163A2 (OSRAM)
ZA (1) ZA201403680B (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
PH12014500940A1 (en) 2011-10-28 2019-06-26 Biogen Int Neuroscience Gmbh Tdp-43 specific binding molecules
WO2014198528A2 (en) 2013-06-11 2014-12-18 Paul Scherrer Institut Method for determining mutateable ligand-gpcr binding at single amino acid resolution and pairs of mutated ligand and gpcr
WO2015117088A2 (en) 2014-01-31 2015-08-06 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
US10556946B2 (en) 2014-07-29 2020-02-11 Neurimmunie Holding AG Human derived anti-Huntingtin (HTT) antibodies and uses thereof
CN104497121A (zh) * 2014-08-29 2015-04-08 苏州顺升桥生物科技有限公司 淀粉样蛋白tdp-43及其用途
EP3200825A4 (en) 2014-10-03 2018-03-21 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
TWI592423B (zh) * 2014-10-03 2017-07-21 中央研究院 可辨識致病性ｔｄｐ－４３之抗體及其用途
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
WO2017111166A1 (ja) * 2015-12-25 2017-06-29 国立大学法人東京農工大学 Ｔｄｐ－４３細胞内存在量関連疾患治療剤
DK3430397T3 (da) 2016-03-14 2022-05-02 Biogen Int Neuroscience Gmbh Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
MA45715A (fr) 2016-07-25 2019-05-29 Biogen Ma Inc Anticorps anti-hspa5 (grp78) et leurs utilisations
MA47163A (fr) 2016-12-16 2019-11-06 Biogen Ma Inc Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
CA3054067A1 (en) * 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
EP3634987A4 (en) * 2017-05-30 2021-03-03 The University of British Columbia EPITOPES IN RNA RECOGNITION MOTIVE 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES
EP4233901A3 (en) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
AU2018338451A1 (en) 2017-09-25 2020-04-02 University Of Florida Research Foundation, Incorporated Immunoassays for detection of RAN proteins
EP3724232B1 (en) 2017-12-14 2024-12-04 The University of Ottawa Exosome packaging and targeted autophagy
US11246857B2 (en) * 2017-12-14 2022-02-15 The Johns Hopkins University Anti-fungal inhibitors
CN111886247A (zh) 2018-01-05 2020-11-03 Ac免疫有限公司 错折叠tdp-43结合分子
JP7320282B2 (ja) * 2018-03-16 2023-08-03 国立大学法人滋賀医科大学 異常ｔｄｐ－４３を分解除去する抗体断片
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
TW202019398A (zh) * 2018-06-28 2020-06-01 張翔毓 用於治療或預防構形疾病之方法及藥物篩選方法
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
CA3117409A1 (en) 2018-10-29 2020-05-07 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
CA3123116A1 (en) * 2018-12-14 2020-06-18 The University Of British Columbia Antibodies to misfolded tdp-43 and methods of use
JP2022533432A (ja) * 2019-05-23 2022-07-22 エイシー イミューン ソシエテ アノニム 抗ｔｄｐ－４３結合分子およびその使用
EP4013773A4 (en) * 2019-08-12 2023-08-23 Macquarie University Compositions and methods for treatment
CA3154741A1 (en) 2019-09-20 2021-03-25 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
GB202004863D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Method
BR112022021604A2 (pt) 2020-04-28 2022-12-06 Sola Biosciences Llc Composições e métodos para tratamento de proteinopatias associadas à tdp-43
KR20230003067A (ko) * 2020-04-29 2023-01-05 더 유니버시티 오브 브리티쉬 콜롬비아 미스폴딩된 tdp-43에 대한 단일쇄 항체 및 인트라바디 그리고 사용 방법
EP4175716A4 (en) * 2020-07-06 2024-08-21 The Board Of Regents Of The University Of Texas System TDP-43 BIOSENSOR CELL LINES
US20230322908A1 (en) * 2020-08-14 2023-10-12 Ac Immune Sa Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
EP4252243A2 (en) 2020-11-30 2023-10-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
AU2022282368A1 (en) * 2021-05-27 2023-11-30 Mayo Foundation For Medical Education And Research Methods and materials for treating proteinopathies
CA3231484A1 (en) * 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
KR20250004705A (ko) * 2022-04-08 2025-01-08 에이씨 이뮨 에스에이 항-tdp-43 결합 분자
WO2023205579A1 (en) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions and methods for disrupting pathological aggregates
WO2023204313A1 (ja) 2022-04-22 2023-10-26 国立大学法人新潟大学 Ｔｄｐ－４３の凝集抑制剤及び医薬組成物
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2024263701A1 (en) * 2023-06-20 2024-12-26 The Trustees Of Dartmouth College Chimeric antigen receptors (cars) targeting tdp43, tregs expressing said cars, and use thereof for the treatment of als, ftd and ad
KR102859015B1 (ko) * 2023-07-20 2025-09-12 충북대학교 산학협력단 ｃ­Ａｂｌ에 의한 ＴＤＰ­４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법
CN116875738A (zh) * 2023-07-24 2023-10-13 山东省农业科学院畜牧兽医研究所 一种鉴定牛tdp-43基因启动子活性区域的方法
WO2025059486A1 (en) * 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
EP0934953A2 (en) * 1997-12-03 1999-08-11 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
US8354236B2 (en) * 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
PL2099826T3 (pl) * 2007-01-05 2014-04-30 Univ Zuerich Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
WO2008151055A1 (en) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
US8940872B2 (en) * 2007-07-06 2015-01-27 Tokyo Metropolitan Institute Of Medical Science Antibody binding specifically to TDP-43 aggregate
CA2713871C (en) * 2008-02-01 2018-05-22 Washington University In St. Louis Sequences associated with tdp-43 proteinopathies and methods of using the same
PT2370466E (pt) 2008-12-19 2015-09-21 Univ Zuerich Autoanticorpos humanos anti-alfa-sinucleína
CN101634656A (zh) * 2009-08-21 2010-01-27 武汉三鹰生物技术有限公司 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒
PH12014500940A1 (en) 2011-10-28 2019-06-26 Biogen Int Neuroscience Gmbh Tdp-43 specific binding molecules

Also Published As

Publication number Publication date
AU2012327211C9 (en) 2016-11-17
IL232219B (en) 2019-11-28
CN104159918A (zh) 2014-11-19
CL2014001074A1 (es) 2015-01-09
US20140255304A1 (en) 2014-09-11
PH12014500940A1 (en) 2019-06-26
IL232219A0 (en) 2014-06-30
US20170152308A1 (en) 2017-06-01
CA3112082A1 (en) 2013-05-02
US10259866B2 (en) 2019-04-16
JP2015505665A (ja) 2015-02-26
EA201490825A8 (ru) 2016-09-30
EP2771359B1 (en) 2021-05-19
JP6417451B2 (ja) 2018-11-07
JP6652609B2 (ja) 2020-02-26
AU2012327211C1 (en) 2016-09-15
IL270223B (en) 2021-05-31
BR112014010161B1 (pt) 2022-02-08
EA032003B1 (ru) 2019-03-29
US11091540B2 (en) 2021-08-17
HK1201846A1 (en) 2015-09-11
KR20140100480A (ko) 2014-08-14
JP6240611B2 (ja) 2017-11-29
WO2013061163A2 (en) 2013-05-02
JP2017205118A (ja) 2017-11-24
KR102032080B1 (ko) 2019-10-15
KR101961508B1 (ko) 2019-03-25
AU2012327211A1 (en) 2013-05-23
SG11201401735WA (en) 2014-05-29
AU2012327211B2 (en) 2016-03-10
MX2018008680A (es) 2023-04-18
BR112014010161A2 (pt) 2018-09-25
NZ624871A (en) 2016-06-24
ZA201403680B (en) 2020-05-27
EP3964524A1 (en) 2022-03-09
EA201490825A1 (ru) 2015-01-30
CA2853412A1 (en) 2013-05-02
CN104159918B (zh) 2019-09-13
US20200017577A1 (en) 2020-01-16
EP2771359A2 (en) 2014-09-03
MY167795A (en) 2018-09-26
CA2853412C (en) 2021-05-04
US9587014B2 (en) 2017-03-07
ES2883212T3 (es) 2021-12-07
MX2014005048A (es) 2014-11-10
KR20180132977A (ko) 2018-12-12
JP2019022500A (ja) 2019-02-14
WO2013061163A3 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
MX357678B (es) Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43).
PH12021550083A1 (en) Human anti-tau antibodies
EA201390453A1 (ru) Человеческие анти-тау антитела
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
CO7160115A2 (es) Proteinas de unión a antigeno que se unen a pd-l1
UY32612A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
EA201790757A1 (ru) Связывающие антиген cd27l белки
AU2011343161A8 (en) Human anti-SOD1 antibodies
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201400579A1 (ru) Антитела к il-36r
MX369148B (es) Agentes de unión kir3dl2.
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: WSP GLOBAL INC.

FG Grant or registration